![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
| Item Type: | Article |
|---|---|
| Title: | The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association |
| Creators Name: | Kridel, R. and Xerri, L. and Gelas-Dore, B. and Tan, K. and Feugier, P. and Vawda, A. and Canioni, D. and Farinha, P. and Boussetta, S. and Moccia, A.A. and Brice, P. and Chavez, E.A. and Kyle, A.H. and Scott, D.W. and Sanders, A.D. and Fabiani, B. and Slack, G.W. and Minchinton, A.I. and Haioun, C. and Connors, J.M. and Sehn, L.H. and Steidl, C. and Gascoyne, R.D. and Salles, G. |
| Abstract: | PURPOSE: We aimed to assess the prognostic significance of follicular lymphoma-associated macrophages in the era of rituximab treatment and maintenance. EXPERIMENTAL DESIGN: We applied immunohistochemistry for CD68 and CD163 to two large tissue microarrays (TMA). The first TMA included samples from 186 patients from the BC Cancer Agency (BCCA) who had been treated with first-line systemic treatment including rituximab, cyclophosphamide, vincristine, and prednisone. The second contained 395 samples from PRIMA trial patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, and randomized to rituximab maintenance or observation. Macrophage infiltration was assessed using Aperio image analysis. Each of the two cohorts was randomly split into training/validation sets. RESULTS: An increased CD163-positive pixel count was predictive of adverse outcome in the BCCA dataset [5-year progression-free survival (PFS) 38% vs. 72%, respectively, P = 0.004 in the training cohort and 5-year PFS 29% vs. 61%, respectively, P = 0.004 in the validation cohort]. In the PRIMA trial, an increased CD163 pixel count was associated with favorable outcome (5-year PFS 60% vs. 44%, respectively, P = 0.011 in the training cohort and 5-year PFS 55% vs. 37%, respectively, P = 0.030 in the validation cohort). CONCLUSIONS: CD163-positive macrophages predict outcome in follicular lymphoma, but their prognostic impact is highly dependent on treatment received. |
| Keywords: | CD Antigens, Cell Surface Receptors, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Follicular Lymphoma, Macrophages, Myelomonocytic Differentiation Antigens, Prognosis, Rituximab, Tissue Array Analysis, Treatment Outcome, Tumor Microenvironment, Vincristine |
| Source: | Clinical Cancer Research |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Volume: | 21 |
| Number: | 15 |
| Page Range: | 3428-3435 |
| Date: | August 2015 |
| Official Publication: | https://doi.org/10.1158/1078-0432.CCR-14-3253 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
